Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies - Episode 1

Prevalence and Testing Strategies for ESR1

,

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the clinical significance of *ESR1* mutations in HR+/HER2- metastatic breast cancer patients, including their impact on disease prognosis, treatment outcomes, and the increasing prevalence of these mutations with each line of endocrine therapy, ultimately informing their therapeutic approach.

  1. What are the clinical implications of ESR1 mutations for disease prognosis and treatment outcomes in HR+/HER2- mBC patients?
    • How does the increasing prevalence of ESR1 mutations with each line of endocrine therapy inform your treatment approach and decision-making process?